TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23265162

Group type: EXPERIMENTAL
Intervention: Multi-surface composites (MSC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel crowns (SSC)
Number of subjects: 40
Study: 18977159

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Oral sustained-release hydromorphone
Number of subjects: 174
Study: 17210048

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 2 at low concentration (0.1 micro g/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 6 at low concentration (0.1 micro g/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 1 at high concentration (100 micro g/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 3 at high concentration (100 micro g/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cumulative SPT response
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eliciting dose (ED)
Number of subjects: 30
Study: 15097240

Group type: EXPERIMENTAL
Intervention: Losartan (25 or 50 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12470179

Group type: EXPERIMENTAL
Intervention: Levetiracetam (3000 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11289465

Group type: EXPERIMENTAL
Intervention: Behavioral-Family Systems Therapy (BFST)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Current Therapy (CT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Education and Support (ES)
Number of subjects: 119
Study: 9286892

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous epinephrine-containing test dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No premedication followed by intravenous test dose containing 3 ml of 1.5% lidocaine + 15 microg epinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: No premedication followed by intravenous saline 3 ml
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous saline
Number of subjects: 18
Study: 7900069

Group type: EXPERIMENTAL
Intervention: BAY U3405 (20 mg four times a day from day 1 to day 3)
Number of subjects: 16
Study: 3226967

Group type: EXPERIMENTAL
Intervention: Superimposed visual stimuli for poetic metaphors (43 writers)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Superimposed visual stimuli for poetic metaphors (46 writers)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Superimposed images for drawings (43 artists)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Superimposed images constructed into a single-image figure-ground display (39 artists)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition for poetic metaphors (43 writers)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition for poetic metaphors (46 writers)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition for drawings (43 artists)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition for drawings (39 artists)
Number of subjects: 171
Study: 1993628

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (60.0 Gy)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Preoperative radiation therapy (50.0 Gy)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (60.0 Gy) in supraglottic larynx patients
Number of subjects: 277

Group type: COMPARATOR
Intervention: Preoperative radiation therapy (50.0 Gy) in supraglottic larynx patients
Number of subjects: 277
Study: 795362

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31471079

Group type: EXPERIMENTAL
Intervention: Hospitalized stroke patients
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Educational status (illiterate/unable to read and write)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Attending secondary school
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Length of hospital stay >5 days
Number of subjects: 364
Study: 31350916

Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg intravenously three times daily, maximum 20 mg daily)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo (isotonic saline 0.9%)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000
Study: 29489982

Group type: EXPERIMENTAL
Intervention: Standardized out‐of‐hospital management method
Number of subjects: 217

Group type: COMPARATOR
Intervention: Dysphagia rehabilitation guidance (Control)
Number of subjects: 217
Study: 26915028

Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Red laser treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 75
Study: 25623461

Group type: EXPERIMENTAL
Intervention: Metformin treatment in PCOS patients (Group B)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Metformin treatment in PCOS patients (Group A)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: PCOS patients with insulin resistance
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 186
Study: 23139614

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression in LNM CRC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression in relation to advanced tumor node metastasis stage
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression and 5‐year recurrence rate
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression and 5‐year overall survival rate
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression as a prognostic factor for recurrence
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression as a prognostic factor for survival
Number of subjects: 96
Study: 19465554

Group type: EXPERIMENTAL
Intervention: CO breathing (1 h/day at 100 parts/million for 5 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CO breathing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vo(2max) testing alone
Number of subjects: 10
Study: 17458361

Group type: EXPERIMENTAL
Intervention: Counseling for care-giving relatives
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study: 15282204

Group type: EXPERIMENTAL
Intervention: Autoadjusted CPAP titration
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Predicted formula titration with domiciliary adjustment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard CPAP titration (polysomnography)
Number of subjects: 360
Study: 12221219

Group type: EXPERIMENTAL
Intervention: Oral dose of [(13)C(5)]pABG (376 nmol or 100 micro g) in 40 mL apple juice
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: [(13)C(5)]pABG administered
Number of subjects: 4

Group type: COMPARATOR
Intervention: Folate intake (450 or 850 micro g/d)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pregnancy status
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Overall contribution of dietary pABG
Number of subjects: 4
Study: 9803329

Group type: EXPERIMENTAL
Intervention: EVITA-2, CPAP 5 mbar
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SV 300, CPAP 5 mbar, flow trigger
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SV 300, pressure trigger - 4 mbar
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EVITA-4, CPAP 5 mbar
Number of subjects: 9

Group type: COMPARATOR
Intervention: SV 300 with 2 mbar pressure support
Number of subjects: 9
Study: 7796721

Group type: EXPERIMENTAL
Intervention: Supervised therapy and dispensing of AZT for eight weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care of the clinic
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supervised therapy and dispensing of AZT
Number of subjects: 27
Study: 2192018

Group type: EXPERIMENTAL
Intervention: PZQ 50 mg/kg per day for 15 days
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: PZQ 50 mg/kg per day for 8 days
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: ALB 15 mg/kg per day for 30 days
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: ALB 15 mg/kg per day for 8 days
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 114
Study: 116273

Group type: EXPERIMENTAL
Intervention: Scopolamine (5 microgram/kg administered IV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30003521

Group type: EXPERIMENTAL
Intervention: Oral maternal vitamin B12 supplementation
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine (tHcy) in the second trimester
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine (tHcy) in the third trimester
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Normal serum total homocysteine (tHcy) levels
Number of subjects: 218
Study: 28687828

Group type: EXPERIMENTAL
Intervention: Lexical feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Somatosensory feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 60
Study: 25725178

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 96
Study: 23529102

Group type: EXPERIMENTAL
Intervention: Auditory feedback with kinetic guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual feedback with kinetic guidance (Control)
Number of subjects: 0
Study: 21507527

Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone protocol (1 mg IV followed by 1 mg IV after 15 minutes if needed)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care (any intravenous opioid at physician's discretion)
Number of subjects: 338
Study: 19142106

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 14
Study: 17381399

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (TOBI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous tobramycin (TOBRA)
Number of subjects: 10
Study: 15133405

Group type: EXPERIMENTAL
Intervention: Propranolol CR 80 mg/d
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Propranolol CR 120 mg/d
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Propranolol CR 160 mg/d
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Propranolol CR 640 mg/d
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 12492136

Group type: EXPERIMENTAL
Intervention: Propranolol (PRO)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLY)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oxygen breathing at SL concentration
Number of subjects: 5
Study: 9799974

Group type: COMPARATOR
Intervention: CDSB Qi-training (more than 13 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CDSB Qi-training (1-4 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CDSB Qi-training (5-12 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CDSB Qi-training (all groups)
Number of subjects: 164
Study: 8745663

Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 mg twice a day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hydroquinidine (300 mg twice a day)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hydroquinidine
Number of subjects: 87
Study: 2762688

Group type: EXPERIMENTAL
Intervention: Clonidine (0.25‐0.3 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 941962

Group type: EXPERIMENTAL
Intervention: Perceptual-motor training program (30 minutes per day, 5 days per week for 10 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perceptual-motor training program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular classroom activities (Control group)
Number of subjects: 40
Study: 31089282

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG: resistance, endurance, and flexibility training)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-exercise control group (CG: mental and relaxation training)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70

Group type: COMPARATOR
Intervention: Exercise intervention group (IG) vs Non-exercise control group (CG)
Number of subjects: 70
Study: 29054505

Group type: EXPERIMENTAL
Intervention: BioMonitor 2 Implantable Cardiac Monitor
Number of subjects: 30
Study: 26439325

Group type: EXPERIMENTAL
Intervention: Pre-HCT Medical Outcomes Study Short Form-36 Health Survey (SF-36) physical component summary (PCS) scale
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Early post-HCT decreases in PCS
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: SF-36 PCS adjusted for patient variables in the US Stem Cell Therapeutic Outcomes Database model
Number of subjects: 646
Study: 25262224

Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy (SP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation (TP/AT)
Number of subjects: 32
Study: 22935584

Group type: EXPERIMENTAL
Intervention: OxCap (oxaliplatin/capecitabine)
Number of subjects: 2397

Group type: COMPARATOR
Intervention: OxFU (oxaliplatin/leucovorin/infusional 5-FU)
Number of subjects: 2397

Group type: COMPARATOR
Intervention: OxFU+cetuximab
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Both regimens (OxCap and OxFU)
Number of subjects: 2397
Study: 20224060

Group type: EXPERIMENTAL
Intervention: simplified mRS questionnaire (smRSq)
Number of subjects: 50

Group type: COMPARATOR
Intervention: structured interview mRS
Number of subjects: 50
Study: 17581320

Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 202

Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 202
Study: 15839851

Group type: EXPERIMENTAL
Intervention: almotriptan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lysine-acetylsalicylate
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 12431829

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (vinorelbine or gemcitabine)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Polychemotherapy (gemcitabine plus vinorelbine)
Number of subjects: 707
Study: 9655013

Group type: EXPERIMENTAL
Intervention: Attended locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unattended locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual quality
Number of subjects: 0
Study: 7659427

Group type: EXPERIMENTAL
Intervention: Sensory examination in the painful area using various stimuli (heat, cold, argon laser, von Frey hair)
Number of subjects: 11
Study: 2664522

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily during the third trimester)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (during the third trimester)
Number of subjects: 65
Study: 178190

Group type: EXPERIMENTAL
Intervention: Long-term hospitalization
Number of subjects: 141

Group type: COMPARATOR
Intervention: Short-term hospitalization
Number of subjects: 141
Study: 31045443

Group type: EXPERIMENTAL
Intervention: Lung ultrasound assessment at baseline (1.15 ± 1.80) and at high altitude (2.56 ± 2.86)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Participants diagnosed with AMS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Change in BLS (ΔBLS) from low altitude baseline
Number of subjects: 103
Study: 27989394

Group type: EXPERIMENTAL
Intervention: Combined functional voice therapy (10-15 individual sessions, 30-40 minutes each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (singers who did not opt for vocal rehabilitation)
Number of subjects: 40
Study: 25687666

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise training regimen (cycle ergometry), 3 days/week for 3 months.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Stretching activities (attention-control condition), same contact time as exercise condition.
Number of subjects: 54
Study: 23196701

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Sulfasalazine and hydroxychloroquine (SSZ+HCQ)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 487
Study: 21531412

Group type: COMPARATOR
Intervention: Multiple 7F double‐pigtail stents (group A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Stents in combination with UDCA and terpene (group B)
Number of subjects: 51
Study: 18460483

Group type: EXPERIMENTAL
Intervention: Flaxseed (40g/day of ground flaxseed-containing baked products)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wheat bran products (control)
Number of subjects: 62
Study: 16307723

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (15 mmol L(‐1) solution dripped onto enamel blocks eight times per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Deionized water (dripped onto enamel blocks eight times per day)
Number of subjects: 12
Study: 12754275

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 10726678

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (PS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (regular clinical and endoscopic examinations)
Number of subjects: 100
Study: 8933117

Group type: EXPERIMENTAL
Intervention: VA-fortified margarine (250 g per week providing 28.8 micrograms retinol equivalents per gram)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Non-fortified margarine (0 microgram retinol equivalents)
Number of subjects: 581
Study: 7956275

Group type: COMPARATOR
Intervention: Sterile gauze and tape (control), replaced every 2 days
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Conventional polyurethane dressing, replaced every 5 days
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Highly permeable polyurethane dressing, replaced every 5 days
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: All groups (gauze, conventional polyurethane, highly permeable polyurethane)
Number of subjects: 442
Study: 3679573

Group type: EXPERIMENTAL
Intervention: Single donor plasma in therapeutic plasma exchange (TPE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Random plasma in therapeutic plasma exchange (TPE)
Number of subjects: 37
Study: 29542008

Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24609848

Group type: EXPERIMENTAL
Intervention: Educational seminar on biospecimen collection
Number of subjects: 395
Study: 22445730

Group type: EXPERIMENTAL
Intervention: White coat
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Traditional dress
Number of subjects: 143

Group type: COMPARATOR
Intervention: Casual
Number of subjects: 143

Group type: COMPARATOR
Intervention: Suit
Number of subjects: 143
Study: 20056199

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19065891

Group type: EXPERIMENTAL
Intervention: WM plus DCHD
Number of subjects: 36

Group type: COMPARATOR
Intervention: WM
Number of subjects: 36

Group type: COMPARATOR
Intervention: WM plus placebo
Number of subjects: 36
Study: 15973099

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 76
Study: 12792453

Group type: EXPERIMENTAL
Intervention: Standard education
Number of subjects: 40

Group type: COMPARATOR
Intervention: Experimental educational intervention
Number of subjects: 40
Study: 10235449

Group type: EXPERIMENTAL
Intervention: Endotoxin (4 ng/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin (1000 mg po)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 30
Study: 7476241

Group type: EXPERIMENTAL
Intervention: Phonological working memory intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pursuit rotor and memory tasks (prior practice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random-number generation task
Number of subjects: 0
Study: 2156945

Group type: EXPERIMENTAL
Intervention: Topical high-dose interferon-alpha (10(6) IU/g with 1% nonoxynol-9 in 3.5% methylcellulose) applied three times daily for 5 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Topical low-dose interferon-alpha (10(3) IU/g with 0.1% nonoxynol-9 in 3.5% methylcellulose) applied three times daily for 5 days
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (3.5% methylcellulose, alone) applied three times daily for 5 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Topical high-dose interferon-alpha
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 396086

Group type: EXPERIMENTAL
Intervention: Labetalol 150 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Labetalol 600 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Labetalol 900 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Labetalol (all doses)
Number of subjects: 24